Molecular Partners Plans 44% Workforce Reduction to Focus on Radiotherapeutics
The Molecular Partners workforce reduction 2026 cuts up to 55 roles as the Swiss biotech focuses on targeted radiotherapy. Key facts and gaps.
Bepirovirsen Market: Size, Forecast and Outlook After FDA Approval
Bepirovirsen market to reach USD 2.12 billion by 2035 at 29.6% CAGR after Hibsago FDA approval. Segments, regional outlook, competitors and adoption hurdles.
India CAR-T Therapy Development: Nucelion, VeGen Bio Pact
India CAR-T therapy development gets a boost as Nucelion and VeGen Bio partner on VL-2511, an experimental dual-target myeloma therapy.
Lycia Therapeutics IPO: $938M Valuation Target, Big Risks
Lycia Therapeutics IPO targets up to a $937.7 million valuation with 14.7 million shares at $16 to $18. Terms, use of proceeds and risks.
AstraZeneca insitro AI Drug Discovery Deal: Bold $1.5B Bet
The AstraZeneca insitro AI drug discovery deal: $40M upfront, up to ~$1.46B in milestones, for MASH and heart disease. What is certain and what is not.
Zealand Pharma Generate Biomedicines Deal: Powerful AI Pact
Zealand Pharma Generate Biomedicines deal: $30M upfront and up to nearly $1.2B in potential milestones for AI-designed obesity drugs. Nothing is guaranteed.
BioNTech mRNA Cancer Therapy Trial: BNT113 Misses PFS Goal
BioNTech mRNA cancer therapy trial: BNT113 missed the PFS endpoint in AHEAD-MERIT, but the study continues to an overall survival analysis.
MT027 CAR-T Therapy FDA Clearance: Phase 2 Brain Trial
MT027 CAR-T therapy FDA clearance: T-MAXIMUM can start a Phase 2 study in lung and breast cancer brain metastases. What the data show and what is missing.
AI Drug Discovery India: ₹86 Crore Boost for Peptris
AI drug discovery India gets a boost as TDB backs Peptris with ₹86 crore to move four AI-found drug candidates toward the clinic. Terms and unknowns.
Iambic Therapeutics IPO Targets $806M Valuation
Nvidia-backed Iambic Therapeutics plans a Nasdaq IPO at $15 to $17 a share, valuing the AI drug discovery firm at up to about $806 million.